Suppr超能文献

接受直接口服抗凝剂治疗的患者在胃肠外科手术期间的围手术期抗血栓管理。

Perioperative antithrombotic management of patients who receive direct oral anticoagulants during gastroenterological surgery.

作者信息

Fujikawa Takahisa, Takahashi Ryo, Naito Shigetoshi

机构信息

Department of Surgery Kokura Memorial Hospital Kitakyushu Japan.

出版信息

Ann Gastroenterol Surg. 2020 Apr 1;4(3):301-309. doi: 10.1002/ags3.12328. eCollection 2020 May.

Abstract

AIM

We investigated the effect of perioperative management of direct oral anticoagulants (DOACs) on bleeding and thromboembolic complications during gastroenterological (GE) surgery.

METHODS

A total of 334 patients receiving anticoagulants and undergoing elective GE surgery between 2012 and 2018 were enrolled. The patients were divided into three groups: patients receiving warfarin (WF, n = 231), patients receiving DOACs with heparin bridging (DOAC-HB, n = 34), and patients receiving DOAC without heparin bridging (DOAC-NHB, n = 69). Outcome variables were compared between the groups and the risk factors of postoperative bleeding were assessed using logistic multivariate analysis.

RESULTS

No significant differences were observed in background characteristics between the groups. There were similarities between the groups in surgical blood loss ( = .772) and rate of intraoperative transfusion ( = .952). Thromboembolic complications only occurred in two patients in the WF group (0.9%), and no thromboembolism occurred in the DOAC groups. The incidence of major postoperative bleeding was significantly higher in DOAC-HB group than in the other groups (14.7% vs 4.8% vs 1.4%,  = .011). Multivariate analysis showed DOAC with heparin bridging to be the most significant risk factor of major postoperative bleeding (odds ratio = 11.60,  = .028).

CONCLUSIONS

Elective GE surgery can be safely performed in patients receiving DOACs without heparin bridging. Perioperative heparin bridging during DOAC interruption is not recommended even for patients undergoing major GE surgery due to increased postoperative bleeding.

摘要

目的

我们研究了直接口服抗凝剂(DOACs)围手术期管理对胃肠外科(GE)手术期间出血和血栓栓塞并发症的影响。

方法

纳入2012年至2018年间共334例接受抗凝剂治疗并接受择期GE手术的患者。患者分为三组:接受华法林治疗的患者(WF,n = 231)、接受DOACs并进行肝素桥接的患者(DOAC-HB,n = 34)以及接受DOACs但未进行肝素桥接的患者(DOAC-NHB,n = 69)。比较各组的结局变量,并使用多因素逻辑回归分析评估术后出血的危险因素。

结果

各组之间的基线特征无显著差异。各组在手术失血量(P = 0.772)和术中输血率(P = 0.952)方面相似。血栓栓塞并发症仅在WF组的2例患者中发生(0.9%),DOAC组未发生血栓栓塞。DOAC-HB组术后大出血的发生率显著高于其他组(14.7% vs 4.8% vs 1.4%,P = 0.011)。多因素分析显示,DOAC联合肝素桥接是术后大出血的最显著危险因素(比值比 = 11.60,P = 0.028)。

结论

接受DOACs且未进行肝素桥接的患者可以安全地进行择期GE手术。即使是接受大型GE手术的患者,也不建议在DOAC中断期间进行围手术期肝素桥接,因为这会增加术后出血的风险。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/111f/7240147/784b1b87e54a/AGS3-4-301-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验